Cyclic Derivatives Modulating MIP-1α Receptor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases, such as rheumatoid arthritis, lack effective modulators for chemokine receptor activity, particularly for MIP-1α and CCR-1 interactions, which are key contributors to inflammatory responses.
Innovation Solution
Development of novel cyclic derivatives that act as antagonists or partial agonists/antagonists of MIP-1α or CCR-1 receptor activity, formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune diseases are used, then existing therapeutic options are available, but effective modulators for chemokine receptor activity (particularly MIP-1α and CCR-1 interactions) are lacking
Solution Approach 1:
The invention segments the chemokine receptor modulation problem by developing specific cyclic derivative compounds that selectively target the MIP-1α/CCR-1 interaction pathway. This segmentation allows for precise modulation of chemokine receptor activity without affecting other immune pathways, thereby improving therapeutic effectiveness while maintaining the ability to address specific disease mechanisms.
Solution Approach 2:
The invention employs parameter changes by designing cyclic derivatives with specific molecular structures (formula I) that alter the binding characteristics to CCR-1 receptors. By modifying structural parameters such as ring size, substituent groups, and stereochemistry, the compounds achieve optimal affinity and selectivity for CCR-1, enabling effective chemokine receptor modulation that was previously unavailable.
2Reliability
If novel cyclic derivatives are developed as antagonists or partial agonists/antagonists of MIP-1α or CCR-1 receptor activity, then effective chemokine receptor modulation is achieved, but the complexity of drug development and formulation increases
Solution Approach 1:
The cyclic derivative compounds of formula (I) exhibit multi-functionality by acting as both antagonists and partial agonists/antagonists depending on specific molecular variations. This universality allows a single compound class to address multiple therapeutic needs in inflammatory and autoimmune diseases, reducing the need for separate drug development programs while maintaining effective chemokine receptor modulation.
Solution Approach 2:
The invention introduces cyclic derivatives as intermediary molecules that mediate the interaction between MIP-1α and CCR-1 receptors. These compounds serve as molecular mediators that can block or modulate the natural ligand-receptor interaction, providing a controllable mechanism for regulating chemokine signaling pathways involved in inflammatory and autoimmune processes.
3Object-affected harmful factors
If compounds targeting MIP-1α/CCR-1 interaction are used, then inflammatory responses are reduced and therapeutic benefits are provided, but the need for specialized pharmaceutical formulations increases
Solution Approach 1:
The cyclic derivative compounds are designed with molecular structures that prioritize rapid clearance and short half-life characteristics. This approach allows for frequent administration of simpler formulations without accumulation of active drug, reducing the need for complex sustained-release formulations while maintaining effective anti-inflammatory activity through repeated dosing of relatively simple pharmaceutical compositions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate MIP-1α and chemokine activity, providing therapeutic benefits in treating inflammatory diseases and autoimmune disorders by targeting the MIP-1α/CCR-1 interaction, thereby reducing inflammatory responses and alleviating symptoms.
Implementation Method 1
The chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins... On binding their cognate ligands, chemokine receptors transduce an intracellular signal
Data Source
AI summary
The present application describes modulators of MIP-1α of formula (I), or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, A, T, R1, R2 and R8, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.